CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
Published on November 16, 2020
LIXTE BIOTECHNOLGY HOLDINGS, INC.
248 Route 25A, No.2
East Setauket, NY 11733
November 16.2020
VIA EDGAR
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-6010
| Re: | Lixte Biotechnology Holdings, Inc. | |
| Registration Statement on Form S-1 (Reg. No. 333-248588) |
Ladies and Gentlemen:
On behalf of Lixte Biotechnology Holdings, Inc., the undersigned hereby requests that the Securities and Exchange Commission issue an order declaring the above-referenced Registration Statement effective at 4:00 P.M., Washington, D.C. time, on Wednesday, November 18,2020 or as soon thereafter as is practicable. Please call our counsel, David Ficksman, at 310-789-1290 to inform him of the effectiveness.
| Very truly yours, | |
| /s/ John Kovach | |
| John Kovach | |
| President and Chief Executive Officer |